CiloTax StentTM - summitMD.com

More documents

Recommendations

Info

Pharmacologic Effects Cilostazol A PDE III inhibitor Pharmacologic Effects - antiplatelet - antiproliferative (VSMC) - EC protection
A Potent Anti-platelet Agent Effects of Cilostazol on Stent Thrombosis 0.5 0.5% Stent thrombosis (%) 0.25 0.0 Dual therapy (n=1,597) P=0.024 0.1% Triple therapy (n=1,415) Compared with the dual antiplatelet regimen, triple therapy was more effective in preventing thrombotic <strong>com</strong>plications after BMS stenting without an increased risk of side effects. Lee SW et al, J Am Coll Cardiol 2005;46:1833
Page 1 and 2: CiloTax Stent TM Dual Drug-eluting
Page 3: Moving Forward Co-drug Eluting Sten
Page 7 and 8: Anti-restenotic Effect DECLARE - Lo
Page 9 and 10: The Ideal Combination? Cilotax TM S
Page 11 and 12: Cilotax Stent TM Polymer & Drugs Po
Page 13 and 14: Safety and Efficacy of the Cilotax
Page 15 and 16: Animal Preparation • Juvenile swi
Page 17 and 18: Analysis • Angiography and IVUS:
Page 19 and 20: Results 3.0 18mm Cilotax BMS 4 week
Page 21 and 22: IVUS Analysis at Follow-Up (n=7) BM
Page 23 and 24: Results BMS (n=3) Cilotax stent (n=
Page 25 and 26: Results Inflammatory Response BMS (
Page 27 and 28: Clinical Study Efficacy and Safety
Page 29 and 30: Objectives • to assess safety and
Page 31 and 32: Study Endpoints • Statistics - a

CiloTax StentTM - summitMD.com

Create successful ePaper yourself

Delete template?

Save as template?